SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Resideo reported second quarter 2026 earnings results with record revenue of $1.98 billion (up 2% YoY), record gross margin of 30.0%, net income of $97 million versus a loss of $825 million in Q2 2025, and Adjusted EPS of $0.83 (up 26% YoY), along with detailed segment performance and forward guidance.
View raw filing on EDGAR →BitGo issued a press release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing total revenue of $4.3 billion (up 79.6% year-over-year) and a net loss of $19.0 million.
View raw filing on EDGAR →Amcor issued a press release on August 12, 2026, disclosing financial results for the fourth quarter and fiscal year ended June 30, 2026. The disclosure includes comprehensive GAAP and adjusted non-GAAP results (net sales, net income, EPS, EBITDA, free cash flow), segment performance, and forward guidance for the transition period. This is a standard earnings release furnished as Exhibit 99.1 under Item 2.02, with material financial metrics showing strong performance (net sales up 57% to $23.5 billion, net income up 116% to $1.1 billion, adjusted EPS up 13% to $4.02).
View raw filing on EDGAR →This exhibit is a press release announcing Jumia's second quarter 2026 financial results, including revenue of $52.0 million (up 14% YoY), gross profit of $30.7 million (up 28% YoY), and narrowed adjusted EBITDA loss of $8.7 million (down 36% YoY). The document also announces a concurrent $50 million capital raise anchored by the International Finance Corporation. As a quarterly earnings announcement with detailed financial metrics and forward guidance reaffirming the path to Q4 2026 breakeven, this is a material earnings release event.
View raw filing on EDGAR →Stem, Inc. issued a press release announcing financial results for Q2 2026 (quarter ended June 30, 2026), disclosing revenue of $33.7M, GAAP gross profit of $13.9M, net loss of $14.4M, adjusted EBITDA of $6.2M, and reaffirming full-year 2026 guidance.
View raw filing on EDGAR →Kontoor Brands issued a press release on August 12, 2026 announcing second quarter fiscal 2026 financial results, including revenue of $584 million (19% increase), adjusted EPS of $1.06 (13% increase), and raised full-year 2026 adjusted EPS guidance to $5.25–$5.35 (27–29% growth). This is a standard quarterly earnings disclosure furnished as Exhibit 99.1 under Item 2.02, materially affecting investor assessment of the registrant's financial performance and outlook.
View raw filing on EDGAR →This is a standard quarterly earnings release for Grocery Outlet's second quarter fiscal 2026 ended July 4, 2026. The filing discloses net sales of $1.19 billion (up 1.1%), operating income of $15.8 million, and net income of $5.6 million ($0.06 per diluted share), along with comparable store sales trends, gross margin, and forward guidance. The press release is furnished as Exhibit 99.1 and constitutes the primary disclosure under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →DeFi Development Corp. issued a press release on August 12, 2026 disclosing Q2 2026 financial results, including revenue of $3.3M (up 67% YoY), net loss of $27.3M, and key operational metrics such as SOL per share growth of 24% year-over-year. The exhibits include the full Q2 2026 Shareholder Letter and Business Update with detailed financial statements, income statement highlights, and forward guidance. This is a standard quarterly earnings disclosure filed under Item 2.02.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure explicitly states "Enovix Corporation (the 'Company') issued a press release announcing the release of its financial results for the second fiscal quarter 2026," with the press release attached as Exhibit 99.1. The exhibit contains detailed financial results including revenue ($9.0M, up 21% YoY), gross profit, net loss per share, and forward guidance—all hallmarks of a quarterly earnings announcement.
View raw filing on EDGAR →The filing discloses positive Phase 2a clinical trial results for NEO100 in recurrent IDH1-mutant high-grade glioma, announced via press release on August 12, 2026. The study met its primary endpoint (six-month progression-free survival of 48.9% vs. 20% benchmark, p=0.0047) with favorable secondary outcomes including median overall survival of 26.09 months and no major toxicities. While this is a clinical-stage biotech company rather than a traditional earnings release, the disclosure of material clinical trial results through a press release furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure) is functionally equivalent to an earnings release—it is a material announcement of significant company results that would affect investor assessment of the registrant's prospects.
View raw filing on EDGAR →The 8-K discloses quarterly financial results for Q2 2026 (quarter ended June 30, 2026) via Item 2.02 and attached press release (Exhibit 99.1). The filing reports significant deterioration: revenue declined 47.4% YoY to $113.3M, gross margin collapsed from +6.0% to -62.9%, and net loss widened to $84.3M ($1.55 per share) versus $10.3M loss in the prior year quarter. The company explicitly attributes the decline to "unfavorable non-cash adjustments related to legacy disputes" and a $93.6M cumulative catch-up adjustment on claims recoverability. This material earnings disclosure would significantly affect investor assessment of the registrant's financial condition.
View raw filing on EDGAR →This is a classic earnings release disclosure under Item 2.02. Connect Biopharma issued a press release on August 12, 2026 announcing financial results for the three and six months ended June 30, 2026, including cash position ($31.5 million), license and collaboration revenues ($2.8 million and $2.9 million for Q2 and H1 respectively), R&D expenses ($16.3 million and $31.3 million), G&A expenses ($4.1 million and $8.8 million), and net loss ($17.3 million and $36.7 million). The press release also provides material business updates on clinical trial milestones (completion of Phase 2 Seabreeze STAT enrollment) and cash runway expectations. This is material to investors as it discloses the company's financial condition and key operational progress.
View raw filing on EDGAR →AEON Biopharma disclosed its second quarter 2026 financial results on August 12, 2026, reporting a net loss of $12.9 million for the six months ended June 30, 2026, a cash position of $3.4 million, and a $15.3 million financing with milestone warrants.
View raw filing on EDGAR →This is a press release announcing Similarweb's Q2 2026 financial results, including revenue of $77.2 million (9% YoY growth), first-ever quarter of positive GAAP operating profit ($0.7M), and raised full-year guidance. The document contains consolidated financial statements, operational metrics (NRR at 100%, ARR surpassing $300M), and forward-looking guidance for Q3 and FY 2026. This is a classic earnings release disclosing quarterly results and material business developments including strong AI demand and $60M in new contracts.
View raw filing on EDGAR →Direct Digital Holdings issued a press release on August 12, 2026, announcing financial results for Q2 2026 and the six-month period ended June 30, 2026. The disclosure includes detailed revenue, gross profit, operating expenses, net loss, and adjusted EBITDA figures for both periods, along with balance sheet data and management commentary. This is a standard earnings release disclosing quarterly and year-to-date financial results, which is the core purpose of Item 2.02 disclosures.
View raw filing on EDGAR →This is a press release announcing Marex Group Limited's second quarter 2026 financial results, including revenue of $695.8m (up 39% YoY), Adjusted Profit Before Tax of $165.9m (up 56% YoY), and Basic EPS of $2.09 (up 103% YoY). The document explicitly states "Marex Group Limited announces second quarter 2026 results" and provides comprehensive financial highlights, performance metrics, and management commentary on quarterly and half-year results. This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →This is a press release announcing Logistic Properties of the Americas' second quarter 2026 unaudited consolidated financial results, with total revenue of $14.7 million (up 26.1% YoY) and NOI of $12.2 million (up 27.0% YoY). The document explicitly states it presents "unaudited consolidated financial results for the second quarter ended June 30, 2026" in accordance with IAS 34 Interim Financial Reporting, and includes detailed financial tables, operating metrics, and CEO commentary on quarterly performance. This is a discrete earnings announcement, not a periodic financial report itself.
View raw filing on EDGAR →Alto Neuroscience disclosed financial results for the fiscal quarter ended June 30, 2026 via a press release furnished as Exhibit 99.1. The disclosure includes consolidated statements of operations showing Q2 2026 net loss of $27.6 million (versus $17.7 million in Q2 2025), R&D expenses of $22.1 million, G&A expenses of $7.0 million, and balance sheet data as of June 30, 2026. This is a standard quarterly earnings release with financial statements and operational highlights, meeting the definition of earnings_release under Item 2.02.
View raw filing on EDGAR →AEVEX Corp. issued a press release on August 12, 2026, announcing financial results for the second quarter ended June 30, 2026, disclosing total revenue of $201.8 million (up 99.5% YoY), net income of $6.7 million (versus a net loss of $11.8 million in Q2 2025), and Adjusted EBITDA of $28.1 million. The filing is structured as Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for quarterly earnings disclosures. The material financial results and forward guidance for full-year 2026 revenue of $700–$720 million and Adjusted EBITDA of $105–$111.5 million would affect a reasonable investor's assessment of the company's performance and prospects.
View raw filing on EDGAR →This is a press release announcing Q2 2026 operating and financial results for Mayfair Gold Corp., explicitly stating "Mayfair Gold Reports Q2 2026 Operating and Financial Results" and directing readers to full financial statements and MD&A. Although the company is development-stage (pre-production), the disclosure of quarterly financial results and operational metrics (project advancement, resource estimates, PFS economics) constitutes a material earnings release that would affect investor assessment of the registrant's progress and financial position.
View raw filing on EDGAR →Smithfield Foods issued a press release on August 11, 2026, announcing second quarter and first-half fiscal 2026 financial results, including net sales of $3.7 billion for Q2 and $7.5 billion for the first half, operating profit of $290 million and $623 million respectively, and diluted earnings per share of $0.60 and $1.23. The filing also includes an updated FY 2026 outlook reflecting macroeconomic headwinds. This is a standard quarterly earnings release disclosure under Item 2.02.
View raw filing on EDGAR →Cardinal Health issued a news release on August 11, 2026, announcing fourth quarter and fiscal year 2026 financial results, including Q4 revenue of $63.7 billion and FY revenue of $254.2 billion, along with GAAP and non-GAAP EPS figures and fiscal year 2027 guidance. The company will host a webcast with the CEO and CFO to discuss the results and outlook.
View raw filing on EDGAR →The filing discloses Middleby Corporation's second quarter 2026 financial results via a press release issued on August 11, 2026. The Item 2.02 section explicitly states "The Middleby Corporation (the 'Company') issued a press release announcing its financial results for the second quarter ended July 4, 2026," with the press release furnished as Exhibit 99.1. The exhibit contains detailed quarterly earnings data including net sales ($875.5M), operating income, adjusted EBITDA, and EPS metrics, along with full-year 2026 guidance, making this a standard earnings release disclosure.
View raw filing on EDGAR →This is a press release announcing Tencent Music Entertainment Group's unaudited financial results for the second quarter ended June 30, 2026. The exhibit discloses total revenues of RMB8.93 billion (5.8% YoY growth), net profit of RMB2.47 billion, and diluted EPS of RMB1.57, along with detailed operational and financial metrics. This is a discrete earnings announcement, not a periodic financial report filing, and would materially affect a reasonable investor's assessment of the company's financial performance and operational trends.
View raw filing on EDGAR →Silicon Laboratories issued a press release on August 11, 2026 announcing its financial results for the fiscal quarter ended July 4, 2026, disclosing revenue of $228 million (up 18% year-over-year), gross margin of 61.6%, and non-GAAP diluted EPS of $0.71 (up 545% year-over-year). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99, which is the standard format for quarterly earnings disclosures.
View raw filing on EDGAR →This exhibit is a notice announcing that Americas Gold and Silver Corporation will release its second quarter 2026 financial results on August 14, 2026, and will host a conference call to discuss those results. The document explicitly states "Americas plans to issue a news release containing second quarter 2026 results before markets open in North America on Friday, August 14, 2026." This is a disclosure of periodic quarterly financial results, which constitutes an earnings release event material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →This is a press release announcing IHS Holding Limited's second quarter 2026 financial results, including revenue of $428.6 million from continuing operations (up 10.4% YoY), Adjusted EBITDA of $245.3 million, and ALFCF of $57.1 million. The document explicitly states "FOR IMMEDIATE RELEASE" and "IHS HOLDING LIMITED REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS" with detailed financial metrics, segment performance, and operational highlights. This is a classic earnings release disclosing quarterly financial results.
View raw filing on EDGAR →DPC Holdings PLC issued a press release on August 11, 2026 disclosing financial results for the second quarter ended June 28, 2026. The release reports record revenue of $269 million (up 34% YoY), adjusted EBITDA of $48 million (up 33% YoY), and provides full-year 2026 guidance of $1,000m–$1,040m revenue and $182m–$187m adjusted EBITDA. This is a standard quarterly earnings disclosure attached as an exhibit to Item 2.02, meeting the definition of earnings_release.
View raw filing on EDGAR →908 Devices announced preliminary financial results for Q2 2026 and fiscal year 2026 via press release furnished as Exhibit 99.1. The disclosure includes detailed quarterly and six-month financial statements (revenue of $16.1M, net loss from continuing operations of $11.9M), updated full-year 2026 revenue guidance (raised to $68.0M–$70.0M), and key operational metrics. This is a standard earnings release under Item 2.02.
View raw filing on EDGAR →Item 2.02 discloses Vireo's financial results for Q2 2026 (three months ended June 30, 2026) via a press release furnished as Exhibit 99.1. The press release reports GAAP revenue of $209.3 million (up 335% YoY), GAAP gross profit of $95.3 million, and adjusted EBITDA of $41.5 million, along with detailed commentary on M&A activity and operational highlights. This is a standard earnings release disclosure material to investors assessing the company's financial performance.
View raw filing on EDGAR →This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 11, 2026. The Item 2.02 disclosure explicitly states "Terrestrial Energy Inc. announced its financial and operating results for the quarter ended June 30, 2026" with the press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated balance sheets and statements of operations showing a net loss of $9.4 million for Q2 2026, along with detailed financial metrics, cash position ($283.4 million), and operational highlights. This is a standard quarterly earnings announcement material to investors.
View raw filing on EDGAR →This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) disclosing financial results including operating expenses, net loss, cash position, and operational highlights. The filing explicitly states "issued a press release that included financial information for its quarter ended June 30, 2026" with the press release attached as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02. The disclosure includes condensed consolidated balance sheets and statements of operations showing a net loss of $3.2 million for Q2 2026 and cash position of $11.3 million, material information for investors assessing the company's financial condition.
View raw filing on EDGAR →The filing discloses Gain Therapeutics' financial results for Q2 2026 (ended June 30, 2026) via a press release furnished as Exhibit 99.1. The press release includes condensed consolidated statements of operations and balance sheets, along with detailed discussion of R&D expenses ($2.1M), G&A expenses ($2.5M), net loss per share ($0.11), and cash position ($13.1M). This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and burn rate.
View raw filing on EDGAR →B&G Foods disclosed financial results for Q2 2026 and the first two quarters of 2026, including net sales, net loss/income, diluted EPS, adjusted EBITDA, and segment results, via press release issued on August 11, 2026.
View raw filing on EDGAR →This is a news release disclosing Franco-Nevada's Q2 2026 financial results, including revenue of $580.9 million (+57% YoY), 132,405 GEOs sold (+18% YoY), operating cash flow of $482.5 million (+12% YoY), and Adjusted EBITDA of $529.7 million (+45% YoY). The document presents quarterly and half-year financial highlights, detailed commodity breakdowns, and portfolio updates. This is a discrete earnings announcement, not a periodic financial report filing, and the results are material to investors assessing the registrant's financial performance and operational trajectory.
View raw filing on EDGAR →This is a straightforward earnings release disclosing Barnwell's financial results for the third fiscal quarter ended June 30, 2026. The Item 2.02 disclosure explicitly states "Barnwell Industries, Inc. issued a press release announcing its financial results for its third fiscal quarter ended June 30, 2026," with the press release furnished as Exhibit 99.1. The exhibit contains detailed quarterly financial metrics including revenue ($3,379,000), net loss ($403,000 consolidated, $440,000 attributable to shareholders), and per-share results ($0.03 loss per share), along with comparative analysis and operational metrics.
View raw filing on EDGAR →This Item 2.02 discloses Anteris Technologies' quarterly financial results for the period ended June 30, 2026, filed as Form 10-Q with the SEC and announced to the ASX. The exhibits include the "Anteris Technologies Announces Results for the Second Quarter of 2026" press release (EX-99.1) and the ASX announcement (EX-99.2) containing condensed consolidated financial statements, revenue figures ($1.5M for six months), and operating losses ($51.7M for six months). This is a standard quarterly earnings release disclosure material to investors assessing the company's financial performance and operational progress.
View raw filing on EDGAR →Broadwind issued a press release on August 11, 2026 announcing Q2 2026 financial results, disclosing revenue of $24.3 million (+67% y/y), a GAAP loss from continuing operations of ($0.7) million, and Adjusted EBITDA of $1.6 million, along with an investor presentation and segment-level results.
View raw filing on EDGAR →Harvard Bioscience issued a press release on August 11, 2026, announcing financial results for Q2 2026 and the six-month period ended June 30, 2026, including revenue of $22.7 million (Q2) and $43.5 million (six months), along with updated full-year 2026 guidance raising revenue growth expectations to 3%-5%. This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1, and is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →This is a press release disclosing Westport's second quarter 2026 financial results, including consolidated revenues ($2.7M vs. $12.5M prior year), net loss from continuing operations ($11.4M vs. $5.1M), and detailed segment performance. The exhibit explicitly states "Westport Reports Second Quarter 2026 Financial Results" and provides comprehensive financial tables and operational highlights typical of an earnings release. The disclosure is material as it reveals significant revenue decline (78%), increased losses, and critically, a going-concern warning that "cash and cash equivalents will not be sufficient to fund our operations through the next twelve months."
View raw filing on EDGAR →This is a press release announcing Ceragon's Q2 2026 financial results, dated August 11, 2026. It discloses quarterly revenues ($93.9 million, up 14.2% YoY), GAAP net loss of $2.1 million, and non-GAAP net income of $1.7 million, along with detailed financial statements (condensed consolidated statements of operations, balance sheets, and cash flows) and updated 2026 full-year guidance. The document explicitly states "Ceragon Reports 2026 Second Quarter Financial Results" and includes CEO commentary on business performance and outlook. This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →This is a straightforward earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure announces financial results including revenues of $235.9 million, net income of $30.9 million, and Adjusted EBITDA of $93.9 million, with the full press release furnished as Exhibit 99.1. The filing includes condensed consolidated financial statements and segment information typical of quarterly earnings disclosures.
View raw filing on EDGAR →ChipMOS Technologies reported second quarter 2026 financial results with revenue of NT$7,383.1 million (up 28.7% year-over-year), gross margin expansion to 18.0%, and net earnings of NT$1.28 per share, marking a return to profitability from a loss in Q2 2025.
View raw filing on EDGAR →This is a clear earnings release disclosing quarterly financial results for the three and six months ended June 30, 2026. The press release, attached as Exhibit 99.1, presents net sales of $102.9 million, net income of $1.5 million ($0.07 per share), adjusted EBITDA of $9.8 million, and other key operating metrics. Item 2.02 explicitly states the company "issued a press release announcing its results for the three months and six months ended June 30, 2026," which is the hallmark of an earnings_release disclosure.
View raw filing on EDGAR →This is a clear earnings release disclosing Kardigan's financial results for the fiscal quarter ended June 30, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing second quarter 2026 financial results with detailed operating expenses, net loss ($116.2 million), cash position ($660.7 million), and per-share metrics. The disclosure is material to investors as it provides the company's quarterly financial performance and cash runway guidance through multiple clinical milestones.
View raw filing on EDGAR →Cardinal Infrastructure Group Inc. issued a press release on August 11, 2026, announcing its financial results for the quarter ended June 30, 2026, including record quarterly revenue of $226.9 million (up 114% year-over-year), adjusted EBITDA of $28.1 million, and updated 2026 full-year guidance to $880–$900 million in revenue.
View raw filing on EDGAR →Upstream Bio disclosed its Q2 2026 financial results and business highlights on August 11, 2026, via a press release furnished as Exhibit 99.1. The disclosure includes quarterly financial statements (balance sheet and statements of operations), operating metrics (R&D and G&A expenses, net loss of $39.7 million), and clinical development updates for its lead program verekitug. This is a standard earnings release for a clinical-stage biotech company, filed under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →Aura Biosciences issued a press release announcing its financial results for Q2 2026 (quarter ended June 30, 2026), disclosing a net loss of $45.6 million, cash position of $323.8 million, R&D expenses of $30.7 million, and G&A expenses of $17.3 million, along with business highlights and operational updates.
View raw filing on EDGAR →This is a clear earnings release disclosing Hemab Therapeutics' financial results for Q2 2026 (quarter ended June 30, 2026), issued on August 11, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing quarterly financial results including cash position ($457.5M), R&D expenses ($20.3M), G&A expenses ($5.7M), and net loss ($24.2M or $0.80 per share), along with corporate and pipeline updates. This is a standard earnings release disclosure material to investors assessing the company's financial condition and operational progress.
View raw filing on EDGAR →CalciMedica issued a press release on August 11, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, disclosing Q2 2026 cash position ($18.6 million), R&D expenses ($2.1 million), G&A expenses ($1.9 million), and net loss ($7.7 million or $0.45 per share). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.
View raw filing on EDGAR →